Fangqi Liu

Dr. Fangqi Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TGTian‐An Guo
Tian‐An Guo
YWYu‐Chen Wu
Yu‐Chen Wu
CTCong Tan
Cong Tan
YJYu‐Tong Jin
Yu‐Tong Jin
WSWei‐Qi Sheng
Wei‐Qi Sheng
YXYe Xu
Ye Xu
Mutations of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status have become an important part of the assessment of patients with colorectal cancer (CRC), while respective clinicopathologic features and prognostic significance in specific stages and related detection strategies remain unclear. We retrospectively analyzed clinicopathologic features and prognosis of 1,834 patients with Stage I–IV colorectal adenocarcinoma. Mutations in KRAS, NRAS and BRAF and DNA MMR status were determined. The mutation rates of KRAS, NRAS and BRAF were 46.4, 3.2 and 3.5%, respectively, and the mismatch repair gene deletion (dMMR) rate was 5.6%. In a multivariate analysis, female, advanced age, tumor type histology, mucinous carcinoma and positive tumor deposits were associated with a high KRAS mutation rate. A high BRAF mutation rate was associated with female, poor differentiation, lymphovascular invasion and positive tumor deposits. Factors associated with high dMMR rates included low age, large tumor size, poor differentiation, Stages I–III. Tumor site was independently associated with KRAS mutation, BRAF mutation and dMMR. KRAS and BRAF mutations were independent risk factors for shorter overall survival (OS) in Stage IV tumors but not in Stage I–III tumors. NRAS mutation was an independent risk factor for shorter OS in Stage I–II tumors. dMMR was independently associated with longer OS in Stage III tumors.

26 October 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
XMXiaoji Ma
Xiaoji Ma
YCYikuan Chen
Yikuan Chen
WTWanxiangfu Tang
Wanxiangfu Tang
HBHua Bao
Hua Bao
SMShaobo Mo
Shaobo Mo
JPJunjie Peng
Junjie Peng
Previous studies on liquid biopsy-based early detection of advanced colorectal adenoma (advCRA) or adenocarcinoma (CRC) were limited by low sensitivity. We performed a prospective study to establish an integrated model using fragmentomic profiles of plasma cell-free DNA (cfDNA) for accurately and cost-effectively detecting early-stage CRC and advCRA. The training cohort enrolled 310 participants, including 149 early-stage CRC patients, 46 advCRA patients and 115 healthy controls. Plasma cfDNA samples were prepared for whole-genome sequencing. An ensemble stacked model differentiating healthy controls from advCRA/early-stage CRC patients was trained using five machine learning models and five cfDNA fragmentomic features based on the training cohort. The model was subsequently validated using an independent test cohort (N = 311; including 149 early-stage CRC, 46 advCRA and 116 healthy controls). Our model showed an area under the curve (AUC) of 0.988 for differentiating advCRA/early-stage CRC patients from healthy individuals in an independent test cohort. The model performed even better for identifying early-stage CRC (AUC 0.990) compared to advCRA (AUC 0.982). At 94.8% specificity, the sensitivities for detecting advCRA and early-stage CRC reached 95.7% and 98.0% (0: 94.1%; I: 98.5%), respectively. Promisingly, the detection sensitivity has reached 100% and 97.6% in early-stage CRC patients with negative fecal occult or CEA blood test results, respectively. Finally, our model maintained promising performances (AUC: 0.982, 94.4% sensitivity at 94.8% specificity) even when sequencing depth was down-sampled to 1X. Our integrated predictive model demonstrated an unprecedented detection sensitivity for advCRA and early-stage CRC, shedding light on more accurate noninvasive CRC screening in clinical practice.

23 November 2018 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
HZHongtu Zheng
Hongtu Zheng
ZWZhenyu Wu
Zhenyu Wu
YWYuchen Wu
Yuchen Wu
SMShanjing Mo
Shanjing Mo
WDWeixing Dai
Weixing Dai
Sanjun CaiSanjun Cai
Sanjun Cai
Anastomotic leakage is still one of the most dreaded complications after anterior resection for rectal cancer. This study aimed to identify risk factors for anastomotic leakage and to create a nomogram for precise prediction of anastomotic leakage after anterior resection for rectal cancer.

1 January 2021 in Experimental Cell Research
Verified
Journal Article
Closed access
HZHongtu Zheng
Hongtu Zheng
SYShan Yu
Shan Yu
CZCongcong Zhu
Congcong Zhu
TGTianan Guo
Tianan Guo
FLFangqi Liu
Fangqi Liu
YXYe Xu
Ye Xu

30 April 2024 in EBioMedicine
Verified
Journal Article
Open access
YXYun Xu
Yun Xu
KLKai Liu
Kai Liu
CLCong Li
Cong Li
MLMinghan Li
Minghan Li
XZXiaoyan Zhou
Xiaoyan Zhou
YXYe Xu
Ye Xu
Both defects in mismatch repair (dMMR) and high microsatellite instability (MSI-H) have been recognised as crucial biomarkers that guide treatment strategies and disease management in colorectal cancer (CRC). As MMR and MSI tests are being widely conducted, an increasing number of MSI-H tumours have been identified in CRCs with mismatch repair proficiency (pMMR). The objective of this study was to assess the clinical features of patients with pMMR/MSI-H CRC and elucidate the underlying molecular mechanism in these cases. From January 2015 to December 2018, 1684 cases of pMMR and 401 dMMR CRCs were enrolled. Of those patients, 93 pMMR/MSI-H were identified. The clinical phenotypes and prognosis were analysed. Frozen and paraffin-embedded tissue were available in 35 patients with pMMR/MSI-H, for which comprehensive genomic and transcriptomic analyses were performed. In comparison to pMMR/MSS CRCs, pMMR/MSI-H CRCs exhibited significantly less tumour progression and better long-term prognosis. The pMMR/MSI-H cohorts displayed a higher presence of CD8+ T cells and NK cells when compared to the pMMR/MSS group. Mutational signature analysis revealed that nearly all samples exhibited deficiencies in MMR genes, and we also identified deleterious mutations in MSH3-K383fs. This study revealed pMMR/MSI-H CRC as a distinct subgroup within CRC, which manifests diverse clinicopathological features and long-term prognostic outcomes. Distinct features in the tumour immune-microenvironment were observed in pMMR/MSI-H CRCs. Pathogenic deleterious mutations in MSH3-K383fs were frequently detected, suggesting another potential biomarker for identifying MSI-H. This work was supported by the Science and Technology Commission of Shanghai Municipality (20DZ1100101).

29 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HZHongtu Zheng
Hongtu Zheng
YWYuchen Wu
Yuchen Wu
TGTianan Guo
Tianan Guo
FLFangqi Liu
Fangqi Liu
YXYe Xu
Ye Xu
Sanjun CaiSanjun Cai
Sanjun Cai
Hypoxia plays an essential role in orchestrating Epithelial‐mesenchymal transition and promoting metastasis of colorectal cancer. However, the underlying mechanisms are still not well elucidated. Here, we present that hypoxic exposure causes endoplasmic reticulum stress and activates the unfolded protein response pathways, which drives GDF15 expression in colorectal cancer cells. Mechanistically, upregulated CHOP led by activated PERK‐eIF2α signaling promotes GDF15 transcription via directly binding to its promoter. Further study implicates that hypoxia‐induced GDF15 is required for the EMT and invasion of colorectal cancer cells; enforced expression of GDF15 promotes the mitochondrial oxidation of fatty acids in colorectal cancer cells. Moreover, the abrogation of GDF15 results in smaller xenograft tumors in size and impaired metastasis. GDF15 is expressed much more in tumor tissues of CRC patients and displays positive correlations with CHOP and HIF1α in mRNA levels. Our study demonstrates a novel molecular mechanism underlying hypoxia‐promoted metastasis of CRC and provides PERK signaling‐regulated GDF15 as a new and promising therapeutic target for clinical treatment and drug discovery.